Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 492 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 492 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $38.73, for a total value of $19,055.16. Following the sale, the chief executive officer now directly owns 660,474 shares of the company's stock, valued at approximately $25,580,158.02. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Twist Bioscience Price Performance

Shares of TWST traded up $5.09 during mid-day trading on Wednesday, hitting $40.27. 2,589,001 shares of the company traded hands, compared to its average volume of 972,929. The business has a 50-day moving average of $42.41 and a 200 day moving average of $44.78. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -11.91 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company's revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.75) EPS. As a group, equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently made changes to their positions in TWST. Versant Capital Management Inc grew its stake in Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter worth $34,000. Banque Transatlantique SA bought a new position in shares of Twist Bioscience in the 4th quarter valued at about $43,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience in the 4th quarter valued at about $58,000.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research reports. Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research note on Friday, March 28th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $54.10.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.